All In Biotech

Drug Trial Radar · NCT07348055

A Study of GR1803 in Systemic Lupus Erythematosus

A Phase Ib/IIa Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GR1803 Injection in Subjects With Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

44

Planned (sponsor's estimate)

Start

Feb 2, 2026

Primary completion

Jun 1, 2027

Study completion Dec 1, 2027

Sponsor

Sponsor type
Industry
First posted
Jan 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus

Conditions

  • Systemic Lupus Erthematosus
  • Auto Immune Disease

Interventions

  • GR1803 injectionBiological

    step-up dosing, Dose and frequency according to the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. incidence of adverse eventTime frame: 52 week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.